A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis
Sponsor: Sanofi
This PHASE1 trial investigates Progressive Multiple Sclerosis and is currently completed. Sanofi leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — May 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Oct 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .